(RTTNews) - Shares of Scholar Rock Holding Corp. (SRRK) surged over 45% on Tuesday morning after the clinical-stage biopharmaceutical company announced positive data from phase 2 trial of spinal muscular atrophy treatment.
SRRK is currently trading at $20.10, up $6.38 or 46.50%, on the Nasdaq.
Scholar Rock said treatment with SRK-015 showed improvements in motor function at six-months. Top-line data from the 12-month treatment period are anticipated in second quarter of 2021.
SRK-015 dose response in the primary efficacy endpoint was observed in the randomized, double-blind cohort, with high dose attaining a 5.6 point mean improvement at six-months over baseline compared to low dose attaining a 2.4 point mean improvement over baseline,
"These interim results are important because they demonstrate the potential of this muscle-directed approach to improve motor function of individuals with Type 2 and Type 3 SMA," said Thomas Crawford, M.D., Professor of Neurology at the Johns Hopkins University School of Medicine and Lead Investigator of the TOPAZ trial.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.